Yasuda Tetsuyuki, Kajimoto Yoshitaka, Fujitani Yoshio, Watada Hirotaka, Yamamoto Shuji, Watarai Takao, Umayahara Yutaka, Matsuhisa Munehide, Gorogawa Shin-ichi, Kuwayama Yasuaki, Tano Yasuo, Yamasaki Yoshimitsu, Hori Masatsugu
Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan.
Diabetes. 2002 Jan;51(1):224-30. doi: 10.2337/diabetes.51.1.224.
A paired homeodomain transcription factor, PAX6, is a well-known regulator of eye development, and its heterozygous mutations in humans cause congenital eye anomalies such as aniridia. Because it was recently shown that PAX6 also plays an indispensable role in islet cell development, a PAX6 gene mutation in humans may lead to a defect of the endocrine pancreas. Whereas heterozygous mutations in islet-cell transcription factors such as IPF1/IDX-1/STF-1/PDX-1 and NEUROD1/BETA2 serve as a genetic cause of diabetes or glucose intolerance, we investigated the possibility of PAX6 gene mutations being a genetic factor common to aniridia and diabetes. In five aniridia and one Peters' anomaly patients, all of the coding exons and their flanking exon-intron junctions of the PAX6 gene were surveyed for mutations. The results of direct DNA sequencing revealed three different mutations in four aniridia patients: one previously reported type of mutation and two unreported types. In agreement with polypeptide truncation and a lack of the carboxyl-terminal transactivation domain in all of the mutated PAX6 proteins, no transcriptional activity was found in the reporter gene analyses. Oral glucose tolerance tests revealed that all of the patients with a PAX6 gene mutation had glucose intolerance characterized by impaired insulin secretion. Although we did not detect a mutation within the characterized portion of the PAX6 gene in one of the five aniridia patients, diabetes was cosegregated with aniridia in her family, and a single nucleotide polymorphism in intron 9 of the PAX6 gene was correlated with the disorders, suggesting that a mutation, possibly located in an uncharacterized portion of the PAX6 gene, can explain both diabetes and aniridia in this family. In contrast, the patient with Peters' anomaly, for which a PAX6 gene mutation is a relatively rare cause, showed normal glucose tolerance (NGT) and did not show a Pax6 gene mutation. Taken together, our present observations suggest that heterozygous mutations in the PAX6 gene can induce eye anomaly and glucose intolerance in individuals harboring these mutations.
配对型同源结构域转录因子PAX6是一种众所周知的眼睛发育调节因子,其在人类中的杂合突变会导致先天性眼部异常,如无虹膜症。由于最近研究表明PAX6在胰岛细胞发育中也起着不可或缺的作用,因此人类PAX6基因突变可能会导致内分泌胰腺缺陷。胰岛细胞转录因子如IPF1/IDX-1/STF-1/PDX-1和NEUROD1/BETA2的杂合突变是糖尿病或葡萄糖不耐受的遗传原因,我们研究了PAX6基因突变成为无虹膜症和糖尿病共同遗传因素的可能性。我们对5名无虹膜症患者和1名彼得斯异常患者的PAX6基因所有编码外显子及其侧翼外显子-内含子连接区进行了突变检测。直接DNA测序结果显示,4名无虹膜症患者存在3种不同突变:1种先前报道过的突变类型和2种未报道的突变类型。与所有突变的PAX6蛋白中多肽截短以及缺乏羧基末端反式激活结构域一致,在报告基因分析中未发现转录活性。口服葡萄糖耐量试验显示,所有PAX6基因突变患者均有以胰岛素分泌受损为特征的葡萄糖不耐受。尽管在5名无虹膜症患者中的1名患者中,我们未在PAX6基因的已鉴定区域内检测到突变,但糖尿病在其家族中与无虹膜症共分离,并且PAX6基因内含子9中的一个单核苷酸多态性与这些疾病相关,这表明可能位于PAX6基因未鉴定区域的一个突变可以解释该家族中的糖尿病和无虹膜症。相比之下,PAX6基因突变是相对罕见病因的彼得斯异常患者表现出正常糖耐量(NGT),且未出现Pax6基因突变。综上所述,我们目前的观察结果表明,PAX6基因的杂合突变可在携带这些突变的个体中诱发眼部异常和葡萄糖不耐受。